Pharmacy and Therapeutics Committee Meeting Record

Date: 10/17/03 Time: 9:00 a.m. – 4:00 p.m. Location: 700 West State Street, East Conference Room Moderator: Thomas R. Young, M.D.

Committee Members Present: Thomas Young, M.D.; Richard Pines, D.O.; George Pfoertner, M.D.; Catherine Gundlach, PharmD; Jeffery Edwards, M.D.; Rick Sutton, RPh; James Schroeder, P.A.; Richard Markuson, RPh; Bob Comstock, RPh; Shawna Kittridge, MHS, RPh;p Steve Montamat, M.D.

Committee Members Absent: Thomas Rau, M.D.

Agenda Item	Presenter	Outcome/Action	Assigned	Due
CALL TO ORDER	Thomas R. Young, M.D.			
Roll Call		Dr. Young called the roll.		
• Reading of Confidentiality Statement		The confidentiality statement was read by Dr. Young.		
COMMITTEE ADMINISTRATIVE ITEMS	Thomas R. Young, M.D.			
• Approval of Minutes from September 19, 2003, Meeting		The minutes from the September 19, 2003, Committee meeting were approved with no changes.		
PUBLIC COMMENT PERIOD		 Public comment was received from the following: Dr. Eugene Sum, Merck – COX-2/NSAIDs Dr. Robert Popoula, Pfizer – COX-2/NSAIDs 		
REVIEW AND DISCUSSION OF CLINICAL DATA	Thomas R. Young, M.D.			
• PPI		The clinical summary is that all drugs in this class are similar in efficacy and safety with the exception of Omeprazole, which has some interactions. It should be noted that medication intolerance will need to be noted in the automated system. It should also be noted that all drugs will be available to participants; however, some will require prior authorization.		
• COX-2		The clinical summary is that efficacy is similar between COX-2s and NSAIDs. They are equally safe with other non-steroidal medications; however, safety with the COX-2 differs between population groups, i.e., allergic reactions, and may be safer than NSAIDs. The general consensus is there is no information that would lead the committee to choose one COX-2 over another.		

Agenda Item	Presenter	Outcome/Action	Assigned	Due
EXECUTIVE SESSION	Committee			
 Presentation and Review of Utilization and Rebate Cost Model Information: PPI COX-2 		Shawna presented utilization and rebate cost model information for PPI and COX-2 for the Committee's review and discussion.		
COMMITTEE RECOMMENDATIONS	Thomas R. Young, M.D.			
• PPI		Committee consensus and recommendation to the Department is Scenario G for PPIs with a prior authorization exemption for three drugs.		
• COX-2		Committee consensus and recommendation to the Department is Scenario C for COX-2s and maintaining prior authorization on these medications.		
PRESENTATION OF HERITAGE SMARTPA SYSTEM	Craig Boon, Heritage Info Systems, Inc.	Craig Boon of Heritage Info Systems presented information on the SmartPA system. It will be in place at the Department starting Monday; however, the POS system in the pharmacies will not be in place until December.		
REVIEW OF DEPARTMENT GUIDELINES FOR STIMULANT MEDICATION	Thomas R. Young, M.D.	The proposed prior authorization criteria for stimulants and Straterra were reviewed with the Committee. ACTION: The criteria for the use of GHB will be provided to the Committee at the next meeting.		
DISCUSSION OF KEY QUESTIONS FOR CENTER FOR EVIDENCE-BASED POLICY	Thomas R. Young, M.D.	The evidence-based group will be moving forward on the ARBs. There are three generic questions that should be asked when making decisions around medications: • Are there any differences in efficacy of these drugs? • Are there any differences in the safety of these drugs? • Is there particular pieces of evidence we should know, i.e., age, race, etc.? Additional questions that the Committee would like to have answered by the AHRQ were discussed. ACTION: Dr. Montamat will review the Committee's additional questions with Dr. Helfand to determine the final questions. Once the final questions have been developed, they will be provided to the Committee for review and comment.		
ADJOURN COMMITTEE MEETING	Thomas R. Young, M.D.	The meeting was adjourned and the next meeting will be held on Friday, November 21, 2003.		

Agenda Item Presenter	Outcome/Action	Assigned	Due	1
-----------------------	----------------	----------	-----	---